Cure My Disease

Don't miss your cure!

 Log in / Sign up

Once-Daily pill shows promise for obesity in japanese patients

NCT ID NCT05931380

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests an experimental once-daily oral drug called orforglipron in Japanese adults with obesity and related health problems like high blood pressure or type 2 diabetes. Participants receive either orforglipron or a placebo for 72 weeks. The main goals are to measure weight loss and the percentage of people who lose at least 5% of their body weight.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental oral drug called orforglipron
What this could lead to
If successful, this could provide a convenient once-daily pill for significant weight loss in people with obesity and related health conditions.
What could go wrong
This is a phase 3 trial, but results may not apply to non-Japanese populations. Side effects and long-term safety are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nutritional disorder Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

  • Fukuwa Clinic

    Chuo-ku, Tokyo, 104-0031, Japan

  • Heishinkai Medical Group ToCROM Clinic

    Shinjuku-ku, Tokyo, 160-0008, Japan

  • Hiroshima Station Clinic

    Hiroshima, 732-0053, Japan

  • Medical Corporation Heishinkai OCROM Clinic

    Suita-shi, Osaka, 565-0853, Japan

  • Medical Corporation Yuga Higashirinkan Kaneshiro Diabetes Clinic

    Sagamihara, Kanagawa, 252-0302, Japan

  • Nihonbashi Sakura Clinic

    Chuo-ku, Tokyo, 103-0025, Japan

  • Nishiyamadou Keiwa Hospital

    Naka, Ibaraki, 311-0133, Japan

  • Ohishi Internal Medicine Clinic

    Tsuchiura, Ibaraki, 300-0835, Japan

  • Osaka Nishiumeda Clinic

    Osaka, 530-0001, Japan

  • Shiraiwa Medical Clinic

    Kashihara, Osaka, 582-0005, Japan

  • Shonan Takai Clinic

    Kamakura, Kanagawa, 247-0055, Japan

  • Sugiura Clinic

    Kawaguchi, Saitama, 332-0012, Japan

  • Takai Internal Medicine Clinic

    Kamakura-shi, Kanagawa, 247-0056, Japan

  • Tokyo-Eki Center-building Clinic

    Chuo-ku, Tokyo, 103-0027, Japan

  • Tsuchiura Beryl Clinic

    Tsuchiura, Ibaraki, 300-0062, Japan

  • Yotsuya Medical Cube

    Chiyoda City, Tokyo, 102-0084, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.